Hybio Pharmaceutical Co., Ltd. Class A · SZSE:300199

Hybio Pharmaceutical Co., Ltd. Class A financial statements

Hybio Pharmaceutical Co., Ltd. Class A's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue966.4M590.2M431.4M704.3M736.0M721.7M614.2M1.26B1.25B855.0M
Cost of revenue402.4M281.5M260.4M194.8M271.9M153.5M133.9M184.3M197.0M169.8M
Gross profit564.0M308.7M171.0M509.5M464.1M568.2M480.3M1.08B1.05B685.2M
Research and development126.9M88.0M161.5M158.7M105.7M143.9M180.3M94.9M89.4M60.4M
Selling, general and administrative117.4M119.5M121.1M101.7M100.3M69.7M162.2M151.2M113.5M129.6M
Operating income218.5M-161.4M-507.5M-370.8M39.1M-574.4M-905.3M-320.3M354.4M277.9M
Depreciation and amortization132.7M148.3M154.9M144.5M135.8M108.7M105.5M100.9M100.4M90.9M
EBITDA351.3M-13.1M-352.6M-226.3M174.9M-465.7M-799.8M-219.5M454.8M368.8M
Interest expense98.0M117.9M125.8M109.7M99.7M65.3M94.5M48.4M25.9M40.7M
Income before tax64.2M-162.4M-511.1M-372.8M33.7M-588.2M-891.3M-333.7M350.5M309.2M
Income tax17.7M4.34M-265.0K5.24M21.1M-6.53M7.05M20.8M17.3M
Net income36.6M-173.7M-513.9M-370.6M30.8M-609.4M-884.8M-340.8M329.7M291.9M
Earnings per share, basic0.04-0.20-0.58-0.420.03-0.69-1.00-0.370.350.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents100.7M94.9M344.0M106.3M138.9M451.6M820.8M1.56B1.27B880.5M
Short-term investments1.23M1.11M160.6M477.7M
Receivables121.6M104.9M152.1M329.9M334.5M355.1M847.3M1.25B1.17B813.8M
Inventory261.4M238.6M152.6M190.0M157.1M186.8M152.0M161.6M142.8M136.6M
Current assets523.6M463.0M683.6M812.3M1.16B1.05B1.89B3.02B2.60B1.84B
Property, plant and equipment1.94B1.99B1.98B1.79B1.33B1.06B965.1M
Goodwill191.1K343.6M872.4M898.6M
Total assets3.15B3.01B3.28B3.61B3.91B4.04B4.72B5.66B5.30B4.46B
Accounts payable262.0M218.3M108.5M129.1M90.7M125.5M130.1M74.4M49.1M53.1M
Current liabilities1.78B1.42B1.42B1.15B743.8M1.11B1.14B831.9M865.0M330.9M
Long-term debt623.4M861.1M938.6M1.02B1.37B1.14B1.27B1.35B458.5M421.2M
Total debt1.50B1.56B1.34B1.71B1.74B1.91B1.76B774.8M417.7M
Total liabilities2.52B2.41B2.49B2.31B2.26B2.36B2.49B2.27B1.41B852.4M
Shareholders' equity614.0M578.6M758.8M1.27B1.58B1.64B2.23B3.39B3.88B3.60B
Shares outstanding883.2M868.3M886.0M883.2M883.2M883.2M883.2M921.0M942.1M884.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations233.9M164.7M-3.54M15.8M156.8M48.0M104.6M47.0M228.6M296.4M
Capital spending-234.4M-115.8M-81.8M-189.8M-199.0M-243.7M-570.2M-365.6M-221.1M-116.1M
Free cash flow-449.8K48.9M-85.3M-174.0M-42.2M-195.7M-465.5M-318.6M-7.39M180.4M
Cash from investing-70.0M147.7M51.7M-178.4M-258.5M-596.0M-419.9M-223.5M-131.0M
Cash from financing-345.5M95.8M-71.1M-253.7M-71.7M-425.2M654.6M393.2M524.4M
Dividends paid-94.8M-111.7M-117.9M-114.8M-115.6M-105.0M-114.6M-252.8M-128.3M-63.1M
Share buybacks-413.2M-105.9M
Change in cash-15.3M-247.4M240.9M-1.51M-276.8M-280.2M-906.7M295.8M387.9M694.8M